在接受心脏毒性化疗剂治疗的患者中,对左心室电机延迟和左心室相位功能的评估
1Department of Cardiology, Amasya University, Sabuncuoğlu Şerefeddin Training and Research Hospital, 05100 Amasya, Turkey.
Medicina (Kaunas, Lithuania)
|September 28, 2024
概括
心脏毒性化疗显著损害了心房的机械和电机功能,增加了心房失律的风险. 这项研究评估了女性患者治疗前后的这些影响.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 医疗成像医学成像
背景情况:
- 心脏毒性化疗剂对心脏功能构成风险.
- 心房干扰是这些治疗的潜在并发症.
- 评估心房功能的变化对于患者管理至关重要.
研究的目的:
- 评估心脏毒性化疗对心房机械和电机械参数的影响.
- 在接受化疗的患者中比较治疗前和治疗后的心脏功能.
- 为了研究化疗和心房功能障碍之间的联系.
主要方法:
- 未来的队列研究设计.
- 包括68名接受心脏毒性化疗的女性患者 (18-50岁).
- 在治疗前后对心房机械和电机械参数进行心声学评估.
主要成果:
- 在化疗后,心房机械参数 (PA 持续时间,LAVmax,LAVmin,LApreA) 显著增加.
- 左心房储和功能下降,被动和主动排空量增加.
- 在心房内电机延迟值中没有显著变化.
- 观察到左心室喷射率 (LVEF) 的降低和心室尺寸的增加.
结论:
- 心脏毒性化疗导致心房机械和电机械功能的显著损害.
- 这些功能性变化表明心房律乱的风险增加.
- 这些发现强调了在心脏毒性化疗期间监测心房功能的必要性.
更多相关视频
相关概念视频
Dysrhythmias V: Evaluating Dysrhythmias
22
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.1. Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
22
Cardiomyopathy II: Dilated Cardiomyopathy
1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1
Cardiomyopathy III: Hypertrophic Cardiomyopathy
1
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
1
Cardiomyopathy V: Interprofessional Care
2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
Heart Failure Drugs: Inotropic Agents
535
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
535
Mitral Stenosis II: Clinical features and Diagnostic Tests
6
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
6


